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Background: The amount of data generated from genome-wide association studies (GWAS) has grown rapidly, but
considerations for GWAS phenotype data reuse and interchange have not kept pace. This impacts on the work of
GWAS Central – a free and open access resource for the advanced querying and comparison of summary-level
genetic association data. The benefits of employing ontologies for standardising and structuring data are widely
accepted. The complex spectrum of observed human phenotypes (and traits), and the requirement for
cross-species phenotype comparisons, calls for reflection on the most appropriate solution for the organisation of
human phenotype data. The Semantic Web provides standards for the possibility of further integration of GWAS
data and the ability to contribute to the web of Linked Data.
Results: A pragmatic consideration when applying phenotype ontologies to GWAS data is the ability to retrieve all
data, at the most granular level possible, from querying a single ontology graph. We found the Medical Subject
Headings (MeSH) terminology suitable for describing all traits (diseases and medical signs and symptoms) at various
levels of granularity and the Human Phenotype Ontology (HPO) most suitable for describing phenotypic
abnormalities (medical signs and symptoms) at the most granular level. Diseases within MeSH are mapped to HPO
to infer the phenotypic abnormalities associated with diseases. Building on the rich semantic phenotype annotation
layer, we are able to make cross-species phenotype comparisons and publish a core subset of GWAS data as RDF
nanopublications.
Conclusions: We present a methodology for applying phenotype annotations to a comprehensive genome-wide
association dataset and for ensuring compatibility with the Semantic Web. The annotations are used to assist with
cross-species genotype and phenotype comparisons. However, further processing and deconstructions of terms
may be required to facilitate automatic phenotype comparisons. The provision of GWAS nanopublications enables a
new dimension for exploring GWAS data, by way of intrinsic links to related data resources within the Linked Data
web. The value of such annotation and integration will grow as more biomedical resources adopt the standards of
the Semantic Web.
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In recent years the amount of data generated from
genome-wide association studies (GWAS) has increased
rapidly. However, the formal representation and description
of those data, especially with regards to phenotype, has
lagged behind. The publication of the first successful
GWAS in 2005 heralded the start of an exciting new era of
genetic research that would go on to contribute substan-
tially to our understanding of disease mechanisms, such as* Correspondence: tb143@leicester.ac.uk
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reproduction in any medium, provided the orthe discovery of novel genes linked to Crohn’s disease and
age-related macular degeneration [1]. By March 2008 over
one hundred GWAS had been published, and that number
was growing nearly exponentially [2]. The rapid rate of
growth has been sustained, and so by the start of 2012, over
one thousand published GWAS papers are available in the
literature (Figure 1; red line).
The database resource GWAS Central [http://www.
gwascentral.org] (established in 2007, then named
HGVbaseG2P [3]) is a comprehensive central collection
of genetic association data with a focus on advanced
tools to integrate, search and compare summary-leveld. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The number of GWAS published and the phenotypes reported each year. Since 2005 there has been year-on-year growth in the
number of published GWAS. The number of phenotypes reported each year has consistently remained higher than the number of studies since
2006, indicating a preference to report individual phenotypic components of a disease. Data from GWAS Central.
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GEN2PHEN project [http://www.gen2phen.org], which
aims to unify human and model organism genetic vari-
ation databases. The modular architecture of GWAS
Central allows the infrastructure to be extended for use
with different types of data, and it is anticipated that
through future support from the BioSHaRE project
[http://www.bioshare.eu], GWAS Central will be extended
to integrate exome and next-generation sequencing data.
Currently, GWAS Central collates data from a range
of sources, including the published literature, collaborating
databases such as the NHGRI GWAS Catalog [4], and
direct submissions from collaborating investigators. A
given study represented in GWAS Central may investigate
the genetic association to a single phenotype, or a range of
phenotypes, associated with a disease of interest. In the
case of multiple phenotypes, “sub-studies” will be reported
as separate experiments. For example, a single GWAS
may identify common genetic variation altering the risk to
type 2 diabetes susceptibility, and so report the results
from single or multiple experiments investigating related
traits such as fasting plasma glucose levels, insulin sensi-
tivity index, insulin response or findings from a glucose
tolerance test. GWAS Central captures this distinction
and reports the individual phenotype tested as well as the
disease of interest.
GWAS Central currently holds 1664 reported phenotypes
(Figure 1; blue line). Identical phenotypes may be described
differently between studies due to inconsistencies asso-
ciated with variations in terminology use and in editorial
style of authors when describing the phenotypes. A prag-
matic solution was required to allow harmonisation of theGWAS phenotype descriptions to facilitate consistent
querying within GWAS Central, and to ensure that the
phenotype data can be accessed and understood using a
semantic standard to allow data integration.
Ontologies for GWAS information
The benefits of ontologies in resolving ambiguity asso-
ciated with divergent and “free-text” nomenclature are well
documented [5]. The issues surrounding the reusability of
phenotype descriptions within GWAS Central are typical
of problems tackled by groups working on the controlled
vocabulary of other model organisms, for example yeast
[6], worm [7] and mouse [8]. In these cases, either new
phenotype ontologies were built or existing ontologies
were applied within a meaningful annotation framework.
The Open Biological and Biomedical Ontologies
(OBO) Foundry is an initiative involving the developers
of life-science ontologies and is tasked with setting
principles for ontology development. OBO’s goal is to
coordinate development of a collection of orthogonal
interoperable biomedical ontologies to support data
integration [9]. The application of two OBO Foundry
principles in particular suggest that the development of
a new ontology to capture human phenotype data
derived from GWAS would not be in the community’s
best interest. These principles assert that new ontologies
must be, firstly, orthogonal to other ontologies already
lodged within OBO, and secondly, contain a plurality of
mutually independent users [10].
One candidate OBO Foundry ontology in name alone -
the Human Phenotype Ontology (HPO) [11] - indicates
immediate overlap with our domain of interest (GWAS
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are also available from the National Center for Biomedical
Ontology (NCBO) BioPortal [12], for example Medical
Subject Headings (MeSH) [13] and the International
Classification of Diseases (ICD) [14]. Despite OBO
Foundry efforts in promoting the creation of orthogonal
ontologies, there is still a high rate of term reuse, with a
recent study reporting 96% of Foundry candidate ontologies
using terms from other ontologies [15]. The prevalence of
term reuse and redundancy between ontologies leaves
potential users asking the obvious question “which
ontology do I use?”.
The ambiguity in arriving at an obvious candidate
ontology can have a devastating effect on system inter-
operability and data interchange. We believe the devel-
opment of a dedicated GWAS phenotype ontology
would compound that problem. Additionally, since 2007
when HGVbaseG2P was established, there has been no
call for a dedicated GWAS phenotype ontology from
other quarters, so also failing the “plurality of users”
principle. Consideration of these factors led us to favour
an approach that involves the application of existing
ontologies within the GWAS Central data model.
Phenotypes, traits, medical signs and symptoms
In the context of the genetic analysis of human disease,
and thus GWAS, the term ‘phenotype’ is used to define
an aggregated set of medically and semantically distinct
concepts. Traits and phenotypes are often considered
synonymous, however they are distinct domains within
Ontology. A trait is a heritable, measurable or identifiable
characteristic of an organism such as systolic blood
pressure. Phenotype is a scalar trait [16], essentially a trait
with a value, such as increased systolic blood pressure.
GWAS typically report findings in relation to traits, for
example “Genome-wide association study identifies eight
loci associated with blood pressure” [17]. Furthermore,
human disease is a complex collection of phenotypic
observations and pathological processes [18]. The diagnosis
of a disease depends upon identifying a set of phenotypes,
which can be either medical signs or symptoms. A medical
sign is an objective indication of a medical characteristic
that can be detected by a healthcare professional such as
blood pressure. A symptom is a subjective observation of
the patient that their feeling or function has departed from
the ‘normal’ such as experiencing pain. GWAS report
genetic associations to diseases, for example, “Candidate
single-nucleotide polymorphisms from a genomewide asso-
ciation study of Alzheimer disease” [19], and also medical
signs and symptoms such as “Genome-wide association
study of acute post-surgical pain in humans” [20].
During the course of this study, which sets out to
implement a strategy for logically describing and distrib-
uting GWAS observations contained within the GWASCentral database resource to support GWAS data
comparison, we examine these differing granularities of
phenotypes (or traits). Nonetheless, in order to aid
readability throughout this manuscript we use the term
‘phenotype’, unless otherwise stated, with the same all-
encompassing meaning assumed by the biologist: namely,
the observable characteristics resulting from the expression
of genes and the influence of environmental factors.
Cross-species phenotype analysis for validating GWAS
A striking advantage of binding human GWAS pheno-
types to an ontology is the ability to extend automatic
cross-species analyses of phenotype and genotype infor-
mation with comparative, suitably annotated, datasets.
The laboratory mouse is a central model organism for
the analysis of mammalian development, physiological
and disease processes [21]. It is therefore understandable
that the mouse has been suggested as an ideal model for
the functional validation of GWAS results [22].
A range of resources are available for the querying of
mouse genotype-phenotype associations, such as: the
Mouse Genome Database (MGD) which contains data
loaded from other databases, from direct submissions,
and from the published literature [23]; EuroPhenome, a
repository for high-throughput mouse phenotyping data
[24]; advanced semantics infrastructure involving develop-
ment of a species-neutral anatomy ontology [25]; and
finally a unified specification for representing phenotypes
across species as entities and qualities (EQ) [26] that has
been proposed to enable the linking of mouse phenotypes
to human diseases and phenotypes for comparative
genome-phenome analysis [27].
A major bottleneck in implementing high-throughput
phenomic comparisons leveraging the above resources is
the absence of a well annotated, controlled and accessible
human disease genotype-phenotype dataset, and the
necessary tools to access it.
Linked GWAS data and the Semantic Web
The Semantic Web builds upon the Resource Description
Framework (RDF) and related standards to give meaning to
unstructured documents on the web to allow data to be
understood, shared and reused. The term “Linked Data” is
commonly used to refer to a specific approach to connect-
ing data, information and knowledge on the Semantic Web
that was not previously linked [28]. These technologies and
approaches have in recent years been slowly but surely infil-
trating the life sciences domain to tackle diverse problems.
A notable recent development is the Semantic Automated
Discovery and Integration framework (SADI) [29], a set of
conventions for using Semantic Web standards to automate
the construction of analytical workflows.
In the field of disease genetics, applications of Semantic
Web technologies range from publishing information held
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text-mining the published scientific literature for mutations
found to affect protein structure and subsequently making
methods and data accessible via the SADI framework
[31,32]. To our knowledge, this has not yet been done with
GWAS data in a comprehensive fashion. In relation to the
Linked Data approach specifically, enhancement of GWAS
datasets (such as those made available via GWAS Central)
with phenotype annotations published in Semantic Web
compatible formats has the potential to facilitate integra-
tion with other, related, Linked Data resources, such as
genes, proteins, diseases and publications [33,34].
The complexity of GWAS data sets and associated
metadata led us to adopt so-called “nanopublications”
[35]; a recently developed framework for publishing one
or more scientific assertions as Linked Data, wrapped
into self-contained “bundles” which also contain the
contextual information necessary for the interpretation
of the assertion, as well as provenance, attribution and
other key metadata. The nanopublishing approach has
already been used to publish locus-specific data [36] and
other biological datasets [37]. Ultimately, by making a
comprehensive GWAS dataset available as nanopublica-
tions we aim to provide a rich addition to the web of
Linked Data, while also allowing researchers who contrib-
ute to primary GWAS publications to be properly attribu-
ted. This latter feature of nanopublications is a compelling
reason for their use, particularly with the recent drive
towards publishing data and metadata and creating
incentives for researchers to share their data [38].
Results
Analysis of ontologies for describing GWAS phenotypes
Several ontologies available from the NCBO BioPortal
could be used to annotate part or all of the phenotypes
described by GWAS. Some of the most relevant ones are
either members of the Unified Medical Language System
(UMLS) BioPortal grouping (for example, MeSH, ICD10
and SNOMED CT [39]) or categorised by BioPortal as
being related to ‘Phenotype’ (for example, HPO). We
attempted to objectively identify which ontology would
be most suitable for the purpose of defining GWAS
phenotypes.
To this end, we defined ontology suitability as the
ability to capture the maximum number of phenotypes
at the level of granularity at which they are described.
Our ambition to find a single ontology capable of
describing the broad spectrum of GWAS phenotypes was
pragmatically driven by a requirement to have a single
ontology to query the entire database against. If we were
to query against the complete ontology graph we would
require all phenotypes to be returned. Therefore, during
this comparative study we would consider an ontology
more suitable if it could describe (either by concept or bysynonym) the condition “Fuchs endothelial dystrophy”
compared to the more general “corneal disease” or, more
generally still, the term “eye disease”.
Since the majority of the ‘phenotype’ descriptions in
GWAS Central are in fact trait descriptions (using the
definition above) we assessed the suitability of HPO,
ICD10, MeSH, SNOMED CT and also the Human
Disease Ontology (DO) [40] for describing GWAS traits.
The results from automatic exact and partial term
mapping (see Methods) showed SNOMED CT and
MeSH to be most suitable for mapping to the 1046
unique descriptions of GWAS traits (Table 1). Both could
be mapped directly, after text normalisation (see Methods),
to just over 20% of the traits exactly (MeSH 20.4% and
SNOMED CT 21%). This compared with exactly mapping
10.8% of the traits with DO, 7% with HPO and 3.7%
with ICD10.
The decision to adopt MeSH as the “backbone” for
GWAS phenotype annotations in GWAS Central was
taken due to MeSH being more familiar to biologists
compared to the clinically focussed SNOMED CT.
MeSH is used by the U.S. National Library of Medicine’s
MEDLINE database to index abstracts and is searchable
in PubMed [41]. By contrast, there are relatively few
research-related implementations of SNOMED CT.
Additionally, SNOMED CT is more difficult to navigate
and manage compared to MeSH, with SNOMED CT
containing just under 400,000 classes compared to just
under 230,000 in MeSH (figures taken from BioPortal).
In addition, we assessed the novel mappings achieved
by each vocabulary (Table 1). Novel mappings occurred
when a free-text phenotype description mapped to a
term in a single ontology. During the exact mapping
process, MeSH uniquely contributed 15.4% of the total
332 exactly mapped terms, followed by SNOMED CT
(9.9%) and HPO (4.8%). However, during the partial
mapping SNOMED CT uniquely contributed 12.2% of
the total 434 partially mapped terms, followed by HPO
(6.9%) and MeSH (6.7%). Inspection of the mapping
results showed that by switching from exact mapping to
partial mapping, a free-text phenotype description such
as “forced expiratory volume” that had previously
uniquely mapped to the MeSH Descriptor “Forced
Expiratory Volume”, could now map to a SNOMED CT
term “Normal forced expiratory volume”. Similarly, the
free-text phenotype description “ventricular conduction”
that could not map to any of the terminologies during the
exact mapping could uniquely map to the SNOMED CT
term “Ventricular conduction pattern” during the partial
mapping. Since HPO made the second highest unique con-
tribution in the partial mappings we assessed the benefits
HPO could make in the annotation of GWAS phenotypes.
The HPO is an ontology of phenotypic abnormalities
that was developed in order to provide a standardised







Unique coverage of the total
automatic mappings made
Exact Partial Exact Partial Exact Partial Exact Partial
Human Disease Ontology (DO) 113 146 10.8% 14.0% 3 1 0.9% 0.2%
Human Phenotype Ontology (HPO) 73 140 7.0% 13.4% 16 30 4.8% 6.9%
International Classification of Diseases (ICD10) 39 81 3.7% 7.7% 0 0 0% 0%
Medical Subject Headings (MeSH) 213 256 20.4% 24.5% 51 29 15.4% 6.7%
Systematized Nomenclature of Medicine
Clinical Terms (SNOMED CT)
220 291 21.0% 27.8% 33 53 9.9% 12.2%
The numbers of mappings achieved for both the exact and partial searches are shown along with the percentage of the total number of GWAS Central
phenotypes this relates to. A total of 1046 distinct trait descriptions were assessed and 332 were exactly mapped and 434 partially mapped to terms in one or
more of the vocabularies. The number of cases where the vocabulary in question is the only vocabulary to map to a particular trait description is given in the
“Number of unique mappings” column, followed by the percentage of the total number of automatic annotations this represents.
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festations [42]. The results from our ontology suitability
analysis indicated that HPO would facilitate unique
mapping of 30 GWAS phenotype descriptions during
the partial mapping process. Manual inspection of these
terms showed they were terms describing medical signs
and symptoms, rather than disease names that have high
coverage in the other ontologies investigated. For
example, HPO can uniquely describe “Coronary artery
calcification” (term identifier HP:0001717) rather than
the disease for which this can be a clinical manifestation
such as in “Gaucher Disease” (MeSH Descriptor identifier
D005776).
The performance of HPO in mapping to GWAS traits
increased from 7% for exact mappings to 13.4% for
partial mappings (Table 1). Since HPO is an ontology of
phenotypic abnormalities it contains many terms where
the string “Abnormal” or similar precedes the trait.
During the partial mapping, traits such as “number of
teeth” mapped to partially related HPO terms such as
“Abnormal number of teeth”, hence the improved per-
formance of HPO in making unique term contributions
during the partial mappings.
Not every medical sign and symptom in the GWAS
Central phenotype description list could be mapped to
HPO, due to either lack of an appropriate term or lack
of a synonym. However, the HPO group seeks commu-
nity engagement and there is a protocol in place for
users to submit required terms for inclusion via the
HPO term tracker [43]. Regular updates of the central
ontology file ensure the changes are disseminated in a
timely manner. In addition, subsets of terms from HPO
are undergoing deconstruction into EQ descriptions
[44], thus facilitating the use of HPO in cross-species
comparisons. These factors made HPO a candidate for
the annotation of individual phenotypic abnormalities
(medical signs and symptoms) within GWAS Central.
The relatively low coverage overall achieved through
automatic term mapping suggests that human decision-making is required during the process of phenotype
curation, in order to ensure the biological meaning is
preserved during the selection of alternative but appro-
priate, lexically distinct, concepts.
Describing phenotypes using MeSH and HPO
MeSH is structured into a hierarchy of Descriptors
(or Headings) under which Terms that are strictly
synonymous with each other are grouped in a Concept
category. The Descriptor/Concept/Term structure is
adopted within GWAS Central. Each GWAS reported in
GWAS Central undergoes a phenotype annotation
process (see Methods). During the annotation process
the original full-text published report of the GWAS is
accessed via PubMed (or via communications with
collaborating groups e.g. pre-publication reports) and all
phenotypes for each experiment are manually curated
with a MeSH Descriptor by a small team of postdoctoral
experts to ensure a high level of quality and consistency.
Where possible, a Descriptor is assigned which is
described by a Term that matches the phenotype under
consideration exactly. Where an exact match cannot be
found then the closest match is sought, usually by selecting
the parent Descriptor in the hierarchy, from where the
curator would expect the exact Descriptor to exist. For
example, the phenotype “sporadic amyotrophic lateral
sclerosis” would be annotated with the MeSH Descriptor
“Amyotrophic Lateral Sclerosis”. If a published report has
been indexed for MEDLINE, this indicates that subject
analysts at the United States National Library of Medicine
have examined the article and assigned the most specific
MeSH terms applicable to the article [41]. In these cases
the GWAS Central curators will consider any phenotype-
related MEDLINE MeSH Descriptors for use alongside any
additional appropriate MeSH Descriptors.
Phenotypes in GWAS Central are annotated at the level
of individual experiments. This is in contrast to the
MEDLINE MeSH annotations made at the level of the
whole publication, which identify phenotypes that are
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Central curators are required to ensure that the correct
phenotypes are associated with the correct experiments,
which in turn are associated with the correct analysis
methods, analysis and sample panels, and genetic
marker datasets as defined by the GWAS Central data
model (definitions of these concepts are available from
the GWAS Central glossary: http://www.gwascentral.
org/info/reference/definitions-and-glossary).
MEDLINE indexing is not available for all articles at
the time of inclusion in GWAS Central. Citations
supplied by publishers are not indexed and are identified
by the citation status tag [PubMed – as supplied by
publisher], for example, the GWAS reported in the art-
icle by Paus et al. (2011) with a PubMed ID of 22156575
[http://www.ncbi.nlm.nih.gov/pubmed/22156575]. There
can also be a delay from a GWAS report being made
available in PubMed to it being indexed for MEDLINE,
during which time the citation is assigned the status tag
[PubMed – in progress] [42]. Since GWAS Central is
frequently updated to ensure it contains the very latest
studies, it is usual for the most recent reports not to
contain MEDLINE MeSH annotations at the time of
import.
The GWAS Central interface allows phenotypes to be
retrieved via browsing the hierarchy of Descriptors (only
Descriptors which are used in annotations are rendered)
or by searching for Terms using an auto-suggest text field.
In cases where a phenotype can be annotated to a
greater resolution using HPO then this is done. In
addition, a process of ontology mapping automatically
annotates phenotypes to the corresponding HPO term
from the original manually assigned MeSH annotation
(see Methods). As with MeSH annotations, a HPO hier-
archy containing only terms annotated to phenotypes can
be browsed from the GWAS Central interface, and terms
and synonyms can be queried using an auto-suggest text
field (Figure 2).
Inferring phenotypes for disease using HPO to OMIM
mappings
The HPO defines the individual phenotypic abnormalities
associated with a disease, rather than the disease itself.
Therefore, when a disease name, such as “Creutzfeldt-
Jakob Syndrome”, is used to describe a GWAS phenotype
then a single HPO term representing the disease will not
exist. Instead, HPO can be used to define the medical
signs and symptoms associated with the disease. The
HPO was originally constructed using data from the
Online Mendelian Inheritance in Man (OMIM) database
[45], and now provides comprehensive annotations of
clinical phenotypes for OMIM diseases [11]. These HPO-
to-OMIM mappings are implemented alongside OMIM-
to-MeSH term mappings in GWAS Central to provideautomatically inferred clinical manifestations described by
HPO for the originally assigned disease annotation
described by MeSH. These phenotypes are “inferred” since
they may or may not be present, or present in differing
severities, in the GWAS participants contributing to a
study. While all participants for a study share the charac-
teristic of having been diagnosed with the disease, it is not
possible to determine from the GWAS report which
medical signs or symptoms contributed to the diagnosis.
The inferred HPO phenotypes indicate which clinical
manifestations could have contributed to the diagnosis.
A search in GWAS Central that returns a pheno-
type report annotated to MeSH disease Descriptor
“Creutzfeldt-Jakob Syndrome” will display the mapping
to the OMIM “Creutzfeldt-Jakob Disease” entry and the
HPO-to-OMIM derived phenotypic abnormalities for
the disease, which include “Confusion” and “Loss of
facial expression”, amongst others (Figure 3).
In summary, all phenotypes in GWAS Central have a dir-
ect MeSH annotation and either a direct HPO annotation,
or a mapped HPO annotation, or a mapped set of HPO
annotations, describing inferred clinical manifestations, for
MeSH disease Descriptors (Figure 4).
Comparing phenotypes using ontologies: a human-mouse
comparative pipeline
The Mammalian Phenotype Ontology (MPO) [46] is used
for classifying and organising phenotypic information
related to the mouse and other mammalian species. MPO
is the de facto standard for annotating mouse phenotypes
in online resources. As a first step towards high-throughput
phenotype comparisons between human and mouse, we
have developed an analysis pipeline for the automatic re-
trieval of human and mouse ontology-annotated phenotype
data for gene orthologs. A public version of this pipeline is
available from the scientific workflow exchange community
website myExperiment [47].
The human-mouse comparative pipeline works as
follows:
 Starting from a list of human gene symbols, the
mouse gene orthologs are determined.
 GWAS Central is then queried for phenotypes
associated with genes on the list for a given p-value
threshold, and the corresponding MeSH annotation(s)
retrieved. Each p-value represents the probability of
obtaining the observed association between a genetic
marker and a phenotype for the dataset, assuming the
null hypothesis is true.
 Next, the MGD is queried for MPO annotation(s)
for the mouse ortholog genes.
 Finally, EuroPhenome is queried for MPO
annotation(s) made to the mouse orthologs for a
given statistical significance limit.
Figure 2 Querying GWAS Central against phenotype ontology annotations. A query for “rheumatoid arthritis” can be made by browsing
either the MeSH or HPO hierarchy and selecting the appropriate term, or by using the auto-suggest text field. Only MeSH Descriptors or HPO
terms used in annotations are displayed in the hierarchies. Only MeSH Terms or HPO terms and synonyms used in annotations are presented as
suggested queries. The bracketed numbers after terms in the hierarchies represent the number of unique experiments annotated to that term.
The first six hits of a total results list of sixteen experiments are shown.
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made for the gene ortholog dataset and can be used for
cross-species comparisons.
The following use case presents an example of the
input and output of the pipeline:
The human BAZ1B gene is known to be deleted in
the development disorder Williams syndrome [48]. A
researcher working on BAZ1B wishes to learn which
phenotypes have been associated with the gene as a
result of GWAS, and also which phenotypes have been
associated with the mouse ortholog Baz1b gene. The
researcher downloads the comparative pipeline from
myExperiment and loads it into the Taverna workbench
[49] installed on their PC.Before running the pipeline the researcher enters the
three required input parameters: the gene “BAZ1B”;
the significant GWAS Central p-value threshold of “7”
(10e-7); and the EuroPhenome statistical significance
limit of “0.00001”. The output includes three annota-
tions from GWAS Central, three annotations from
EuroPhenome as a result of the high-throughput
phenotyping of a Baz1b knockout mouse line, and 28
annotations from MGD derived from published and
other sources (Table 2). Manual inspection of these results
shows that both GWAS Central and EuroPhenome
annotations relate to lipid phenotypes (e.g. the GWAS
Central MeSH annotation “Triglycerides” and the
EuroPhenome MPO annotations “decreased circulating
Figure 3 Inferred phenotypes from OMIM as displayed in a GWAS Central “Phenotype Report”. The phenotypic abnormalities associated
with Creutzfeldt-Jakob Syndrome are listed under the OMIM term they are mapped to. A single MeSH disease Descriptor is associated with this
GWAS experiment and the mappings are implemented ‘under the hood’ to provide clickable links to the mapped OMIM and HPO terms.
Screenshot taken of http://www.gwascentral.org/phenotype/HGVPM172.
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esterol level”).
Follow-up searches of the primary data held in the
respective databases are carried out to understand the
annotations. GWAS Central shows a genetic marker in
the BAZ1B gene (SNP rs1178979) with a high probability
(p-value 2e-12) of being associated with genetically
determining triglycerides, as determined during a GWAS
involving white European and Indian Asian participants
(see http://www.gwascentral.org/study/HGVST626). Euro-
Phenome shows that during the “Clinical Chemistry”
procedure of a high-throughput phenotyping pipeline
[50], the male Baz1b heterozygous knockout mouse line
was detected as having decreased circulating cholesterol
(p-value 7.76e-7) and HDL cholesterol (p-value 8.20e-6)
levels compared to the background mouse strains.
Taken together, these findings tentatively suggest a role
for BAZ1B and its ortholog as a genetic determinant of
circulating lipids in the human and mouse. The MGD
annotations do not include a “lipid-type” phenotype,
which may imply that this genotype-phenotype association
has not been reported in the literature for the mouse.
Based on the reported association of the BAZ1B gene
with the circulating lipid phenotype, and knowing that the
Baz1b knockout mouse line is available (since annotations
were obtained from EuroPhenome), the researcher couldnow prioritise further investigation of the BAZ1B gene
and its orthologs.
Genotype to phenotype associations as nanopublications
We designed and created nanopublications (following the
OpenPHACTS guidelines [51] where possible), related
resources, and a query tool for RDF-based GWAS data in
GWAS Central. To this end, we attempted to reuse ontol-
ogies and to link to existing resources. Figure 5 shows a
schematic representation of a GWAS nanopublication and
its connection to other external, semantically-enabled,
resources. The entire nanopublication dataset, created
from the primary GWAS Central relational database, has
also been loaded into a triple-store. The triple-store can be
queried through the GWAS Central SPARQL end-point.
To execute a SPARQL query against the triple-store a
researcher can either enter a query in the “GWAS Central
SPARQL query form” page (accessible from the start page),
or via the API by sending an HTTP GET or POST
request containing a ‘query’ parameter to the web service
[http://fuseki.gwascentral.org/gc/query].
It is important to note that since nanopublications are
entirely RDF based and intended for consumption by
machines, by themselves they are not human-readable.
For user-friendly tools to query and visualise the infor-
mation contained within GWAS Central, researchers are
Figure 4 The phenotype annotation process in GWAS Central as applied to three different phenotypes. Manual annotations are made
using the GWAS Central curation tool. Solid black lines denote direct manual annotations and the dotted black lines denote automatically
mapped annotations. ‘Phenotype A’ is manually annotated with a more specific term from HPO. ‘Phenotype B’ is annotated with MeSH and the
HPO term is automatically mapped. ‘Phenotype C’ is annotated with a MeSH disease Descriptor and is mapped to the inferred HPO phenotypic
abnormalities via OMIM.
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[http://www.gwascentral.org].
With two use cases we can illustrate the application of
SPARQL queries against GWAS Central to gain bio-
logical insight. Figure 6 shows the SPARQL query used
by a researcher who wants to obtain an RDF graph of
genes, their associated markers and the p-values for all
key associations, with a p-value threshold of 10e-7, from
nanopublications related to coronary artery disease
(knowing the MeSH Descriptor identifier for coronaryartery disease is “D003324”). Figure 7 shows the
SPARQL query used by a researcher who wants to
retrieve all MeSH and HPO terms and associated
information (including external marker IDs) from
nanopublications where there are one or more p-values ≤
10e-10.
Further information on using the Semantic Web
resources available through GWAS Central is available
from the website help pages [http://www.gwascentral.
org/info/web-services/semantic-web-resources].
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The pipeline was used to search for annotations relating to the human BAZ1B
gene and its mouse ortholog. The human phenotype annotations (GWAS Central)
are made using MeSH and the mouse phenotype annotations (EuroPhenome
and MGD) are made using MPO. A GWAS Central p-value threshold of “7” (10e-7)
and a EuroPhenome statistical significance level of “0.00001” were used. All MGD
annotations associated to the mouse Baz1b gene were returned.
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Selecting a suitable ontology and annotating phenotypes
We adopted the use of MeSH to define GWAS phenotypes
to meet the overriding requirement of being able to capture
and organise all data within a single ontology for querying
and comparison within GWAS Central. While SNOMED
CT scored slightly higher in our automatic annotationanalysis compared to MeSH, there are doubts over the
suitability of SNOMED CT for use by biomedical
researchers. SNOMED CT is a clinical terminology, and
has been adopted by the NHS for use as a coding standard.
However, concerns have been raised regarding its complex-
ity having a detrimental impact on finding data coded to it
[52]. MeSH is more intuitive to biomedical researchers and
has been shown to be capable of annotating all GWAS
phenotypes at an informative level of granularity, albeit at a
coarser granularity than originally described in some cases.
In order to assist our phenotype annotation process
we have investigated the use of text-mining and mark-up
tools to automate the extraction of relevant phenotype
ontology terms from the GWAS literature. We focussed
on the annotation of GWAS phenotypes with MeSH,
since MeSH forms the “backbone” of GWAS Central
annotations. A range of tools are available for the automatic
annotation of free-text with MeSH Terms (see [53] for a
review of four distinct methods for classifying text with
MeSH). We investigated two tools that are well documen-
ted and are currently supported: the NCBO Annotator [54]
and MetaMap [55]. Both tools were used to annotate a
subset of ten full-text GWAS articles with MeSH Terms.
Curators also assessed the same subset and assigned
MeSH Terms manually following the GWAS Central
phenotype annotation process (see Methods).
While a detailed analysis of how the automated tools
performed is out of the scope of this article, there was
one commonality. Both tools could assign MeSH Terms
(including phenotype-relevant terms) to GWAS studies
as a whole, however during the manual annotation
process MeSH Terms could be assigned to individual
GWAS experiments in keeping with the GWAS Central
data model. Currently, GWAS Central represents studies
that are described in 147 different journal titles, with
varying editorial styles. GWAS metadata is complex and
understanding the associations between participant
panels, methods, observations and genetic marker datasets,
as required by the data model, can be challenging for
expert curators.
For these reasons, we conclude that there is currently
little benefit in incorporating automatic text-annotation
using the tools we have evaluated. Nonetheless, we are
encouraged to further investigate the possibility of build-
ing on the principles of these tools and to develop an
advanced text-mining and annotation strategy for future
use in GWAS Central.
In the intervening years since the inception of
HGVbaseG2P, and subsequently GWAS Central, com-
plementary GWAS databases have embraced the benefits
of using controlled vocabularies for the description of
phenotypes. Two GWAS databases that currently make
use of controlled vocabularies are the DistiLD database
[56] and GWASdb [57].
Figure 5 A schematic representation of GWAS nanopublications and their relationship to the Semantic Web and Linked Data. Example
concepts in the assertion, condition and provenance sections of a nanopublication are shown, along with connections to GWAS Central RDF
resources (markers and phenotypes) and external Linked Data resources. Key external resources include MeSH and HPO, scientific articles indexed
in PubMed, genes (through Bio2RDF), dbPedia [68], the Ontology for Biomedical Investigations [69] and the Publishing Roles Ontology [70]. RDF
data for specific resources is provided via URIs for individual GWAS Central nanopublications, markers and phenotypes. Arrows indicate
connections between resources; lines indicate resources are part of a collection (e.g. Bio2RDF). “NP” is used to denote “nanopublication”.
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SNPs to linkage disequilibrium blocks and diseases
where ICD10 is used to define the diseases. ICD10 is an
ideal vocabulary for the description of disease phenotypes,
but, as expected, resolution is lost when querying the data-
set for non-disease traits. For example, a search for “blood
pressure” on the main search page [http://distild.jensenlab.
org] simply returns results from free-text searches of the
publication titles and abstracts.
GWASdb (reported in 2011) allows exploration of genetic
variants and their functional inferences, incorporating data























FILTER (xsd:float(?pvalue) <= 
}
Figure 6 An example SPARQL query for use case 1. The SPARQL query
graph of genes, their associated markers and the p-values for all key associ
related to coronary artery disease.percent of phenotypes in GWASdb are mapped to DOLite
and the remainder are mapped to HPO [57]. This prevents
the use of a single ontology to query against the complete
dataset. It is also unclear from the interface as to the level
of granularity of the annotations, with only the first four
levels of HPO accessible from the browser. By contrast,
GWAS Central annotates up to level nine of HPO and it is
therefore difficult to assess whether GWAS Central and
GWASdb annotations agree for a given study.
A wider question remains as to the reproducibility of
phenotype annotations between databases and the inter-
















10e-7 && ?meshterm = mesh:D003324)
run by a researcher who wants to use GWAS Central to obtain an RDF














optional {?phenotype gc:hpoAnnotation ?hpoterm}
}
FILTER (xsd:float(?pvalue) <= 1e-10)
}
Figure 7 An example SPARQL query for use case 2. The SPARQL query run by a researcher who wants to use GWAS Central to retrieve all MeSH
and HPO terms and associated information (including external marker IDs) from nanopublications where there are one or more p-values≤ 10e-10.
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databases to ensure a unified set of annotations exist,
mapped to all relevant semantic standards in use in the
community (see the “GWAS PhenoMap” project at
http://www.gwascentral.org/gwasphenomap/).
Cross-species phenotype analysis
Our human-mouse phenotype comparison pipeline facil-
itates immediate retrieval of ontology-bound phenotype
data for orthologous genes. Orthologous genes that do
not share a phenotype could be novel candidates for the
phenotype and thus could benefit from undergoing
further study.
Phenotypes can be logically defined using ontologies by
making an equivalence between terms in a pre-composed
ontology (e.g. MeSH, HPO and MPO) and entity and
quality (EQ) decompositions [26]. For example, the MPO
term “supernumerary teeth” is represented in EQ as “E:
tooth + Q: having extra physical parts” (taken from the
OBO Foundry mammalian phenotype logical definitions).
Comparison of the phenotypes generated from our
pipeline is currently a manual process, but this could be
optimised through using the EQ logical definitions of
the pre-composed ontology terms. This would provide
computer-interpretable definitions that could support
reasoning to suggest, for example, that the MPO term
“supernumerary teeth” and the HPO term “Increased
number of teeth”, represented by the same logical
definition (using a species-neutral anatomy ontology),
are equivalent.
Encouragingly, work has begun on decomposing HPO
musculoskeletal related terms into EQ definitions for the
purpose of cross-species comparisons [44]. As the EQ
definition layer is progressed by domain experts into
other categories of phenotypes covered by HPO, the
possibility of making GWAS phenotypes available as EQ
statements advances closer.In an alternative approach, the PhenoHM human-
mouse phenotype comparison server accepts phenotypes
as input, rather than genes, and implements direct map-
pings from human (HPO) to mouse (MPO) ontologies
[58] to identify human and mouse genes with conserved
phenotypes. By comparison, our pipeline provides the
flexibility to allow phenotypes from any ontology to be
manually compared (from any database providing the
relevant web services) and in theory the PhenoHM
mappings could be extended to include MeSH and other
ontologies. However, evaluation is required of the benefits
of producing relatively quick ad hoc mappings between
terminologies compared to a more time-consuming logical
definition process that could facilitate more extensive
cross-ontology comparisons.
Whichever method is employed, it will make reversing
the pipeline an attractive possibility. Lists of orthologous
phenotypes could serve as input for querying against
human and mouse resources to retrieve associated
genes, in order to answer questions such as “which gene
is responsible for this phenotype in the mouse?”. In the
immediate term we anticipate that the rich, high-quality
GWAS phenotype annotations in GWAS Central will
enhance the results of current and future cross-species
comparisons involving the human.
Semantic GWAS data nanopublishing
By making genotype-phenotype associations available in
a Linked Data-friendly form [59], GWAS Central has
taken the first steps towards interoperability on the
Semantic Web. Our prototype nanopublications were
designed to link with and mesh into the broader web of
Linked Data, by way of shared URI identifiers and ontol-
ogies for identifying and describing key entities in our
domain of interest. This first-generation collection of
GWAS nanopublications, though limited in scope and
features, holds great potential for enriching the expanding
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resources in the biomedical sphere.
It is important to emphasise that GWAS Central
nanopublications are simply items of data, not statements
of knowledge. For example, a p-value for a marker in a
GWAS represents a statistical test of association that was
factually observed in an experiment. This p-value is
clearly not equivalent to a validated biological causal rela-
tionship between a genetic variant and a disease. There is
some risk that eventual users of the data may confuse the
two, especially given that GWAS nanopublications will be
distributed widely and consumed outside of the “parent”
GWAS Central resource itself. This is not a reason to
avoid nanopublishing as such, but it does underline the
importance of including appropriate metadata describing
context and provenance along with, and clearly linked to,
the core assertions.
As new tools are developed to reduce the technical
knowledge required to semantically enable resources
(e.g. the D2RQ Platform [60] and Triplify [61]) and leave
bioinformaticians with the job of simply organising their
data, it seems obvious that increasing numbers of biomed-
ical resources will become semantically enabled in the near
future. As and when this happens, we intend to further
expand the set of Linked Data resources that our GWAS
nanopublications link out to, thereby increasing their utility
when consumed by other semantic tools. We are also plan-
ning to further expand the semantic capabilities of GWAS
Central by exposing the association nanopublications, the
SPARQL endpoint and the phenotype comparison pipeline
(and future workflows we may develop) via the SADI
framework.
Conclusions
We have made available high-quality phenotype annota-
tions within a comprehensive GWAS database. We have
considered the spectrum of phenotypes reported by pub-
lished GWAS, ranging from diseases and syndromes to
individual medical signs and symptoms, and adopted a
suitable annotation framework to capture phenotypes at
the finest level of granularity. All GWAS phenotypes are
bound to a MeSH Descriptor to ensure the pragmatic
necessity that a single ontology can be queried to
retrieve all phenotype data. The HPO provides single
phenotypic abnormality annotations either directly, mapped
from MeSH, or inferred via deconstructions of disease
phenotypes. A human-mouse phenotype comparative pipe-
line provides a valuable tool for comparison of human and
mouse phenotypes for orthologous genes.
By providing GWAS Central data in the form of nano-
publications and integrating this data into the Linked Data
web, we present a platform from which interesting and
serendipitous findings related to genotypes, phenotypes,
and potentially other types of Linked Data, can be made.Methods
Analysis of ontologies for describing GWAS phenotypes
In order to assess ontology suitability (defined as “the
ability to capture the maximum number of phenotypes
at the level of granularity at which they are described”),
we compared our phenotype/trait descriptions against
terms in BioPortal. Initially, we exported the 1046
unique ‘phenotype’ free-text descriptions obtained from
the published GWAS reports and other external sources to
a tab-separated file, resulting in a text list of phenotypes.
Before the list was compared against ontologies, the text
was made consistent (normalised) through a combination
of manual and automated steps:
1. In a manual step all descriptions were assessed to
determine if they related to a trait or phenotype. To
ensure consistency in the descriptions, and since the
majority of descriptions related to traits, phenotypes
were transformed to traits. This involved the removal
of values assigned to traits e.g. “Hair color: black
versus red” was transformed to the trait “Hair color”.
2. Since the ontologies under investigation express
concepts in the singular form, we ran a script to
remove plurals from the trait list.
3. British and American spellings are not synonymous
in all ontologies, for example the HPO term
“Abnormality of the esophagus” (HP:0002031) does
not have the synonym “Abnormality of the
oesophagus”. Therefore, British and American
spelling differences were neutralised by providing
both spellings for a word. A script split each trait
description (term) into component strings (words)
and queried the words against a list of words with
spelling variants (source: http://en.wikipedia.org/wiki/
Wikipedia:List_of_spelling_variants). Where a word
was found to have a spelling variant a new term was
created containing the word with the alternative
spelling. The new term was appended, tab-separated,
to the original term in the trait list.
The BioPortal REST web services allow for programmatic
querying and comparison of the ontologies contained
within BioPortal. In order to access the web services users
are required to login to BioPortal to obtain an API key. The
‘Search’ web service queries a user-specified term against
the latest versions of all BioPortal ontologies, thus eliminat-
ing the need to parse the latest version of an ontology in its
native file format (e.g. OWL, OBO, UMLS format or cus-
tom XML). The ‘Search’ web service ignores capitalisation
of both the user-specified term and the ontology terms. By
default, the search attempts to find both partial and exact
matches. During a partial search for a single word the wild-
card character (*) is automatically appended to the end of
the word, and for multiple-word searches the wildcard
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next stage of our analysis involved running a script to query
each trait description against all BioPortal ontologies using
the ‘Search’ web service. The web service was run twice for
each term, with alternating ‘exact match’ arguments – this
argument forces an exact match. During both runs for each
trait description, the input was the normalised term, for
example “Hair color”. The web service output was queried
for matches in the ontologies of interest, namely DO, HPO,
ICD10, MeSH and SNOMED CT. If a spelling variant did
not return a match in at least one of the ontologies of
interest, then the spelling alternative was also queried, for
example “Hair colour”. The query term and the mapped
ontology term were written to an output file. The total
numbers of trait descriptions that map exactly and partially
to the ontologies under investigation were recorded
(Table 1). When a trait was mapped to a single term in only
one of the ontologies (a unique mapping), the query term,
the mapped ontology term and the ontology name were
written to a second output file. The number of unique
mappings for each ontology during the exact and partial
searches was recorded (Table 1).
Ontology annotation and mapping
The initial ontology association between a phenotype
and a genetic marker dataset is made during a manual
curation process with the subsequent mappings made
automatically. We use the MOLGENIS database man-
agement platform [63] as the basis for a curation tool.
The GWAS Central data model can be viewed and
edited through a series of connected forms (Figure 4).
For each GWAS represented in GWAS Central a curator
obtains the full-text report for the study and adds a new
“sub-study” for each experiment. As the information is
obtained from reading the report, the metadata for each
experiment is entered into the curation tool to satisfy the
GWAS Central data model, resulting in an experiment
that is associated with sample panels, phenotype methods,
analysis methods and a genetic marker dataset (see the
GWAS Central glossary: http://www.gwascentral.org/info/
reference/definitions-and-glossary). Each phenotype method
contains a phenotype property that requires a phenotype
annotation. The relevant MeSH Descriptor identifier is
entered into the form. If a curator deems the annotation
not to be an exact match, and instead the annotation is
made using the closest available term, then this is flagged
in the database. In these cases an appropriate HPO term
will be manually sought.
MeSH is automatically mapped to HPO via UMLS.
The cross-referenced UMLS concept unique identifier
for a HPO term is obtained either from the source HPO
OBO file [http://compbio.charite.de/svn/hpo/trunk/src/
ontology/human-phenotype-ontology.obo] or via MetaMap
[55], which maps free-text to the UMLS Metathesaurus.The MeSH identifier is then obtained from the cross-
referenced UMLS entry. The HPO-to-OMIM mappings
are automatically extracted from the mapping file down-
loaded from the HPO group’s website [http://compbio.
charite.de/svn/hpo/trunk/src/annotation/]. The OMIM-
to-MeSH mappings are manually assigned.
Phenotype comparison pipeline
The human-mouse phenotype comparison pipeline uses
the web services made available by the contributing data
sources to ensure the latest data is accessed. A number
of web services were used to return mouse ortholog
genes for a list of human gene symbols and then return
the corresponding annotated phenotypes for both sets.
The Entrez Programming Utilities (E-Utilities) ESearch
service [64] is used to validate the given list and retrieve
Entrez IDs for the genes. The gene symbols for the
mouse orthologs are retrieved from the MGI BioMart
[65]. The MGI and EuroPhenome BioMarts are accessed
to retrieve the MPO terms annotated to the mouse
ortholog gene list. The GWAS Central REST web service
is accessed to retrieve the phenotype annotations for the
human gene list. The public version of the pipeline was
created using the workflow management system Taverna
[49]. Taverna offers users the ability to visualise and reuse
web services within workflows via the Taverna workbench,
which is an intuitive desktop client application. Taverna is
also integrated with myExperiment, so facilitating the
distribution of the pipeline and its reuse by the community
in whole or in part.
RDF and nanopublications
To provide semantically enabled GWAS Central resources
and integrate them into the Linked Data web, Perl modules
originally created to search markers, phenotypes, associ-
ation results and nanopublications in GWAS Central were
extended to provide output in RDF, Turtle and in the case
of nanopublications, N-Quads format. When navigating
resources, the format to be returned to client applications
is determined either through HTTP header content-type
negotiation (application/rdf + xml, text/turtle or text/
x-nquads), or through the use of a 'format' parameter
(rdfxml, turtle or nquads) in the URI.
A Perl script utilising the above-mentioned search
modules extracted all appropriate resources from GWAS
Central as RDF, which were subsequently loaded into an
RDF triple-store created using the Apache Jena TDB
component [66]. Jena was selected due to its support for
the named graph extension that is an essential requirement
for representing individual sections within nanopublica-
tions. The SPARQL end-point was set up using the
Fuseki server [67].
Using the methodology of other GWAS data resources
[4], we deem results with a p-value less than 10e-5 as
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nanopublications. An example GWAS nanopublication
and its associated connections with key external
resources [68-70] are shown in Figure 5.
Availability of supporting data
The GWAS Central phenotype annotations can be
queried and viewed from the web interface at: http://www.
gwascentral.org/phenotypes.
The GWAS Central SPARQL end-point can be
accessed at: http://fuseki.gwascentral.org.
The human-mouse comparative phenotype pipeline
described in this paper, named “get human and mouse
phenotypes for a gene”, is available from myExperiment
at: http://www.myexperiment.org/workflows/2131.html.
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